WO2002015937A3 - Pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend polyol-fettsäure-ester - Google Patents

Pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend polyol-fettsäure-ester Download PDF

Info

Publication number
WO2002015937A3
WO2002015937A3 PCT/EP2001/009596 EP0109596W WO0215937A3 WO 2002015937 A3 WO2002015937 A3 WO 2002015937A3 EP 0109596 W EP0109596 W EP 0109596W WO 0215937 A3 WO0215937 A3 WO 0215937A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacologically active
fatty acid
acid esters
pharmaceutical composition
active ingredients
Prior art date
Application number
PCT/EP2001/009596
Other languages
English (en)
French (fr)
Other versions
WO2002015937A2 (de
Inventor
Stephan Rimpler
Sabine Grapatin
Cliff Krein
Markus Thelen
Original Assignee
Sanol Arznei Schwarz Gmbh
Stephan Rimpler
Sabine Grapatin
Cliff Krein
Markus Thelen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh, Stephan Rimpler, Sabine Grapatin, Cliff Krein, Markus Thelen filed Critical Sanol Arznei Schwarz Gmbh
Priority to JP2002520858A priority Critical patent/JP4491193B2/ja
Priority to EP01983443A priority patent/EP1313510B1/de
Priority to SI200130226T priority patent/SI1313510T1/xx
Priority to AU2002214953A priority patent/AU2002214953A1/en
Priority to DK01983443T priority patent/DK1313510T3/da
Priority to AT01983443T priority patent/ATE279209T1/de
Priority to US10/344,863 priority patent/US7309497B2/en
Priority to DE2001504138 priority patent/DE50104138D1/de
Publication of WO2002015937A2 publication Critical patent/WO2002015937A2/de
Publication of WO2002015937A3 publication Critical patent/WO2002015937A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

Die vorliegende Erfindung betrifft neue pharmazeutische Zusammensetzungen zur systemischen Verabreichung pharmakologisch aktiver Wirkstoffe. Insbesondere betrifft die Erfindung injizierbare pharmazeutische Zusammensetzung umfassend (a) einen pharmakologisch aktiven Wirkstoff in fester Phase, (b) ein Vehikel, das im wesentlichen aus Polyol-Fettsäure-Estern mit einem Veresterungsgrad von über 80% besteht, (c) ein Netzmittel, das im wesentlichen aus Polyol-Fettsäure-Estern mit einem Monoester-Anteil von über 60% besteht. Die erfindungsgemässe Zusammensetzung ist zur systemischen Verabreichung zahlreicher pharmakologisch aktiver Wirkstoffe geeignet, wobei die Wirkstoffe über einen Zeitraum von mindestens 12, bevorzugt mindestens 24 Stunden aus der pharmazeutischen Zusammensetzung freigesetzt werden.
PCT/EP2001/009596 2000-08-24 2001-08-21 Pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend polyol-fettsäure-ester WO2002015937A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2002520858A JP4491193B2 (ja) 2000-08-24 2001-08-21 新規の医薬品組成物
EP01983443A EP1313510B1 (de) 2000-08-24 2001-08-21 Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
SI200130226T SI1313510T1 (en) 2000-08-24 2001-08-21 Injectable pharmaceutical composition for systemic delivery of pharmacologically active compounds comprising medium chain triglycerides
AU2002214953A AU2002214953A1 (en) 2000-08-24 2001-08-21 Pharmaceutical composition for the systematic administration of pharmacologically active ingredients containing polyol fatty acid esters
DK01983443T DK1313510T3 (da) 2000-08-24 2001-08-21 Injicerbar farmaceutisk sammensætning til systemisk administration af farmakologisk aktive aktivstoffer indeholdende middelkædede triglycerider
AT01983443T ATE279209T1 (de) 2000-08-24 2001-08-21 Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
US10/344,863 US7309497B2 (en) 2000-08-24 2001-08-21 Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients
DE2001504138 DE50104138D1 (de) 2000-08-24 2001-08-21 Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041478A DE10041478A1 (de) 2000-08-24 2000-08-24 Neue pharmazeutische Zusammensetzung
DE10041478.8 2000-08-24

Publications (2)

Publication Number Publication Date
WO2002015937A2 WO2002015937A2 (de) 2002-02-28
WO2002015937A3 true WO2002015937A3 (de) 2002-07-18

Family

ID=7653576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009596 WO2002015937A2 (de) 2000-08-24 2001-08-21 Pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend polyol-fettsäure-ester

Country Status (11)

Country Link
US (1) US7309497B2 (de)
EP (1) EP1313510B1 (de)
JP (1) JP4491193B2 (de)
AT (1) ATE279209T1 (de)
AU (1) AU2002214953A1 (de)
DE (2) DE10041478A1 (de)
DK (1) DK1313510T3 (de)
ES (1) ES2227301T3 (de)
PT (1) PT1313510E (de)
SI (1) SI1313510T1 (de)
WO (1) WO2002015937A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
GB0323979D0 (en) * 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
WO2005053667A1 (en) 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP3085683B1 (de) 2006-02-10 2020-04-29 DuPont Tate & Lyle Bio Products Company, LLC Zusammensetzung beinhaltend ein extrakt und 1,3-propandiol aus biologischer quelle als nichtreizendes lösungsmittel
PL2462990T3 (pl) 2006-06-15 2014-05-30 Ucb Pharma Gmbh Kompozycja farmaceutyczna obejmująca lakozamid i lewetyracetam o synergistycznym działaniu przeciwdrgawkowym
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
DK2101570T3 (da) * 2006-12-14 2013-05-27 Teva Pharma Tannatsalt af rasagilin
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
US8592477B2 (en) * 2007-11-28 2013-11-26 Ucb Pharma Gmbh Polymorphic form of rotigotine and process for production
EP2299993A4 (de) * 2008-06-19 2014-08-20 Teva Pharma Verfahren zum reinigen einer rasagilin-base
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2281559A1 (de) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmazeutische Zusammensetzung enthaltend Rotigotin (Salze oder Na), insbesondere für Iontophorese
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
SI2515887T1 (sl) 2009-12-22 2018-10-30 Ucb Biopharma Sprl Polivinilpirolidon za stabilizacijo trdne disperzije nekristalinične oblike rotigotina
EP2881120B1 (de) * 2012-08-06 2019-08-07 Kangwon National University University-Industry Cooperation Foundation Zusammensetzung mit einem c-peptid zur prävention oder behandlung von diabetischer retinopathie
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
JP6363115B2 (ja) * 2013-02-28 2018-07-25 ミラ ファーマ コーポレイション 注射可能局所麻酔半固体製剤およびその組成物
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541710A (en) * 1975-07-18 1979-03-07 Ciba Geigy Ag Anthelintic preparations
GB2105589A (en) * 1981-09-11 1983-03-30 Wellcome Found Injectable suspensions containing maleic acid or a salt thereof as a stabilising agent
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
GB2232082A (en) * 1989-06-01 1990-12-05 Bimeda Res Dev Ltd Sustained release amoxycillin preparation

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637740A (en) * 1969-04-21 1972-01-25 Pfizer Aminobenzocycloalkane compounds
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US3954983A (en) * 1975-04-28 1976-05-04 Richardson-Merrell Inc. Triazolobenzocycloalkylthiadiazine derivatives
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US5108991A (en) * 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4117156A (en) 1975-07-18 1978-09-26 Ciba-Geigy Ag Anthelmintic preparations
US4054488A (en) 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
EP0026848B1 (de) 1979-09-14 1983-05-04 Sandoz Ag Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten
US4556676A (en) 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4320148A (en) * 1980-11-24 1982-03-16 Smithkline Corporation 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity
CH649300A5 (de) 1981-08-07 1985-05-15 Sandoz Ag Ergopeptinderivate, ihre herstellung und verwendung.
US4465692A (en) 1982-01-03 1984-08-14 Nelson Research & Development Company Selective D-2 dopamine receptor agonist
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4657925A (en) * 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
US5256661A (en) 1983-01-03 1993-10-26 Whitby Research, Inc. Substituted 2-aminotetralins and pharmaceutical use
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US4882352A (en) 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US4743618A (en) * 1983-01-03 1988-05-10 Nelson Research & Development Co. Substituted 2-aminotetralins
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
US4501890A (en) * 1983-09-26 1985-02-26 Eli Lilly And Company Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US4540691A (en) 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4885308A (en) 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3535929A1 (de) 1985-10-04 1987-04-09 Schering Ag 1,2-disubstituierte ergolinderivate
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
AU592629B2 (en) 1986-01-31 1990-01-18 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes and their uses
US5218113A (en) * 1986-01-31 1993-06-08 Whitby Research, Inc. N-substituted thiolactams
US4886783A (en) 1986-01-31 1989-12-12 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4772933A (en) 1986-02-03 1988-09-20 General Electric Company Method for compensating operationally-induced defects and semiconductor device made thereby
US4755535A (en) * 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US4801586A (en) * 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5142044A (en) 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
US5073544A (en) 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4917896A (en) * 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5118845A (en) * 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US4902676A (en) * 1986-09-29 1990-02-20 Nelson Research & Development Co. Compositions comprising N,N-dialkylalkanamides
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
FR2613365B1 (fr) 1987-04-01 1989-07-28 Adir Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
US5066655A (en) 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5273757A (en) 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US5071645A (en) 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
ES2032570T3 (es) * 1987-11-20 1993-02-16 Farmitalia Carlo Erba S.R.L. Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US4996199A (en) * 1988-04-08 1991-02-26 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5118692A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhances for transdermal delivery of systemic agents
US5234959A (en) 1988-04-08 1993-08-10 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5118676A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4908208A (en) * 1988-04-22 1990-03-13 Dow Corning Corporation Matrix for release of active ingredients
US4840796A (en) * 1988-04-22 1989-06-20 Dow Corning Corporation Block copolymer matrix for transdermal drug release
US4951657A (en) 1988-04-22 1990-08-28 Dow Corning Corporation Heat sealable membrane for transdermal drug release
US4931270A (en) * 1988-07-07 1990-06-05 Nelson Research & Development Method for detecting dopaminergic diseases using fluorine-18 radiolabelled D2 dopamine receptor ligands
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
DE3827561C1 (de) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4865920A (en) 1988-09-20 1989-09-12 Dow Corning Corporation Hot-melt pressure sensitive adhesive article and method of making
US4882377A (en) 1988-09-21 1989-11-21 Dow Corning Corporation Low-viscosity pressure-adherent silicone elastomer compositions
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5358971A (en) 1989-07-05 1994-10-25 Whitby Research, Inc. Substituted 2-aminotetralins
US5274003A (en) 1989-07-05 1993-12-28 Whitby Research, Inc. Substituted 2-aminotetralins
US5252335A (en) 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5118704A (en) * 1989-08-30 1992-06-02 Whitby Research, Inc. Substituted 2-aminotetralins useful as dopaminergics
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5071875A (en) 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
USRE36494E (en) * 1990-02-20 2000-01-11 Discovery Therapeutics, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5246997A (en) 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5147916A (en) 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5162410A (en) 1990-04-13 1992-11-10 Dow Corning Corporation Hot-melt silicon pressure sensitive adhesives with phenyl-containing siloxane fluid additive and related methods and articles
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5256398A (en) 1990-11-08 1993-10-26 Whitby Research, Inc. Composition for determining viability of tissue
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US6086905A (en) * 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
EP0641320B1 (de) 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
US5176643A (en) * 1991-04-29 1993-01-05 George C. Kramer System and method for rapid vascular drug delivery
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5232702A (en) 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5300299A (en) * 1991-07-22 1994-04-05 Dow Corning Corporation Silicone pressure sensitive adhesive containing alkylmethylsiloxane wax and related methods and devices
JPH0555856A (ja) 1991-08-22 1993-03-05 Tdk Corp Ｌｃフイルタ
US5273755A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
JPH06234631A (ja) * 1992-12-16 1994-08-23 Takeda Chem Ind Ltd フマギロール誘導体の安定医薬組成物
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
TW280819B (de) * 1993-11-17 1996-07-11 Sumitomo Pharma
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US5442117A (en) 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
IT1276522B1 (it) * 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
AU703593B2 (en) * 1995-06-07 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6010877A (en) * 1997-01-10 2000-01-04 Smithkline Beecham Corporation cDNA clone HE8CS41 that encodes a novel 7-transmembrane receptor
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
ID26033A (id) * 1998-04-02 2000-11-16 Novartis Ag Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
WO2003007803A2 (en) * 2001-07-20 2003-01-30 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US7065626B2 (en) * 2002-07-10 2006-06-20 Hewlett-Packard Development Company, L.P. Method for changing computer system memory density
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541710A (en) * 1975-07-18 1979-03-07 Ciba Geigy Ag Anthelintic preparations
GB2105589A (en) * 1981-09-11 1983-03-30 Wellcome Found Injectable suspensions containing maleic acid or a salt thereof as a stabilising agent
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
GB2232082A (en) * 1989-06-01 1990-12-05 Bimeda Res Dev Ltd Sustained release amoxycillin preparation

Also Published As

Publication number Publication date
EP1313510B1 (de) 2004-10-13
JP2004506697A (ja) 2004-03-04
WO2002015937A2 (de) 2002-02-28
US7309497B2 (en) 2007-12-18
AU2002214953A1 (en) 2002-03-04
SI1313510T1 (en) 2005-04-30
ATE279209T1 (de) 2004-10-15
DK1313510T3 (da) 2005-02-14
US20030180332A1 (en) 2003-09-25
EP1313510A2 (de) 2003-05-28
PT1313510E (pt) 2005-01-31
JP4491193B2 (ja) 2010-06-30
ES2227301T3 (es) 2005-04-01
DE10041478A1 (de) 2002-03-14
DE50104138D1 (de) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2002015937A3 (de) Pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend polyol-fettsäure-ester
HUP0202762A2 (hu) Szilárd lipid készítmények, eljárás az előállításukra és alkalmazásuk
WO2001066089A3 (en) Pharmaceutical compositions comprising cannabis
AU3708599A (en) Use of pharmaceutical compositions capable of being gelled in periodontology
YU76503A (sh) Farmaceutski aktivni estri uridina
IE940583L (en) Topical antimicrobial pharmaceutical compositions
EP1147766A3 (de) Arzneimittel
WO2007092085A3 (en) Fragranced therapeutic delivery system
CA2346001A1 (en) Controlled release nanoparticulate compositions
WO2002067864A3 (en) Coenzyme q products exhibiting high dissolution qualities
HRP20010779B1 (en) Pharmaceutical composition
IL142535A0 (en) Pharmaceutical compositions for the treatment of inflammation
KR950007873A (ko) 생리 활성 물질 지속 방출형의 의약 제제
JO2324B1 (en) Pharmaceutical compounds for topical oral use
WO2002058634A3 (en) ESTRADIOL-16α-CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS
AU2001260180A1 (en) Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
WO2004085345A3 (en) 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS
IE790821L (en) Steroid-containing composition
AU2421601A (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
WO2005110360A3 (en) Compositions for injection
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification
WO2003070194A3 (en) Amino acid and peptide-modified forms of glucocorticoids
CA2572498A1 (en) Biphasic capsule formulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001983443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10344863

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002520858

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001983443

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001983443

Country of ref document: EP